Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights

This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided.& nbsp;Patient summary: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented. (C)& nbsp;2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Automated summary

This article focuses on a 73-year-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma and treated with systemic therapy. It discusses current guideline-based treatment options, the role of cytoreductive nephrectomy and metastasis directed therapies in managing metastatic RCC, as well as various systemic targeted and immune therapies choices. Insights into future developments in treatment pathways are also provided.